肿瘤负荷在3期淋巴瘤试验中的定义与应用:一项综合文献综述
该综述分析了87项3期随机试验,涵盖滤泡性淋巴瘤、弥漫大B细胞淋巴瘤、外周T细胞淋巴瘤和霍奇金淋巴瘤,发现肿瘤负荷的阈值定义(5 cm至10 cm及纵隔肿块比>1/3)和应用方式(入组资格66%、分层24%、预后因素37%、风险适应治疗决策29%)高度不一致,仅5项研究显示负荷对生存差异有显著性。
要点
- 各淋巴瘤亚型最常用负荷阈值:FL 7 cm(58%)、DLBCL 7.5 cm和10 cm(各44%)、PTCL 7.5 cm(66%)、HL 纵隔肿块比>1/3(91%)。
- 负荷阈值用于入组资格(66%)、分层(24%)、预后因素(37%)和风险适应治疗决策如放疗(29%),但定义在亚型间、亚型内甚至单试验内(25%)不一致。
- 32项研究将负荷纳入预后分析,仅5项显示对生存差异有显著性。
核心结论
- 3期淋巴瘤试验中肿瘤负荷的阈值定义及其在入组、分层、治疗风险适应和预后判断中的应用高度不一致,亟需国际共识以改善其预后和预测价值并优化临床应用。
研究设计与样本
- 综合文献综述,评估滤泡性淋巴瘤(FL)、弥漫大B细胞淋巴瘤(DLBCL)、外周T细胞淋巴瘤(PTCL)和霍奇金淋巴瘤(HL)4种主要淋巴瘤亚型的3期随机试验中肿瘤负荷的定义、应用及预后影响,共纳入87项研究。
主要发现
- 使用的负荷阈值范围广泛,包括5 cm、6 cm、7 cm、7.5 cm、10 cm和纵隔肿块比>1/3。
- 各亚型最常用阈值:FL为7 cm(58%);DLBCL为7.5 cm和10 cm(各44%);PTCL为7.5 cm(66%);HL为纵隔肿块比>1/3(91%)。
- 负荷阈值用于确定入组资格(66%)、分层(24%)、作为预后风险因素(37%)以及作为风险适应治疗决策工具如放疗(29%)。
- 负荷定义在淋巴瘤亚型之间、亚型内部甚至单个试验内部(25%)存在差异。
- 32项研究将负荷纳入预后分析,仅5项显示对差异生存结局有显著性。
关键数值与推荐
- FL最常用负荷阈值为7 cm(58%)。
- DLBCL最常用负荷阈值为7.5 cm和10 cm(各44%)。
- PTCL最常用负荷阈值为7.5 cm(66%)。
- HL最常用负荷阈值为纵隔肿块比>1/3(91%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor "bulk" has historically been considered an important prognostic marker and a clinical tool to guide treatment in patients with lymphoma. However, its use and definitions in trial designs vary significantly, and it is unclear how this has influenced the relevance of bulk in contemporary practice. This comprehensive literature review evaluated the definitions, applications, and prognostic impact of bulk in phase 3 randomized trials in 4 major lymphoma subtypes. Overall, 87 studies were identified across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), and Hodgkin lymphoma (HL) with a wide range of bulk thresholds used (5 cm, 6 cm, 7 cm, 7.5 cm, 10 cm, and >1/3 mediastinal mass ratio [MMR]). The most common threshold was as follows: FL, 7 cm (58%); DLBCL, 7.5 cm and 10 cm (44% each); PTCL, 7.5 cm (66%); and HL, one-third MMR (91%). Bulk threshold was used by trials to determine eligibility (66%), stratification (24%), as a prognostic risk factor (37%), and as a decision tool for risk-adapted treatment, for example, radiotherapy (29%); however, bulk definitions used for these varied both between, and within, lymphoma subtypes and even within single trials in 25%. Furthermore, 32 studies incorporated bulk in prognostic analyses with only 5 showing significance for differential survival outcomes. Our analysis demonstrates high inconsistency in thresholds defining tumor bulk and use of bulk in phase 3 lymphoma trials across eligibility, stratification, therapeutic risk adaptation, and prognostication. This highlights an urgent need for international consensus on definitions of bulk within trials to improve its prognostic and predictive values and refine its application in clinical practice.
引用
- Wang L, Chung E, Wellard C, et al. Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Adv. 2025. PMID: 39825862. doi:10.1182/bloodadvances.2024015072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。